Schedule 13D Amendment No. 15

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7(b) for other parties to whom copies are to be sent.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Pursuant to Rule 13d-2 promulgated under the U.S. Securities Exchange Act of 1934, as amended (the “Exchange Act”), this Schedule 13D/A (this “Amendment No. 15”) amends and supplements the Schedule 13D filed on November 24, 2010 (the “Original Schedule 13D”, as amended and supplemented by the Schedule 13D/A filed on December 13, 2010, the Schedule 13D/A filed on December 17, 2010, the Schedule 13D/A filed on March 3, 2011, the Schedule 13D/A filed on May 26, 2011, the Schedule 13D/A filed on May 31, 2011, the Schedule 13D/A filed on December 13, 2011, the Schedule 13D/A filed on December 19, 2011, the Schedule 13D/A filed on June 5, 2012, the Schedule 13D/A filed on May 1, 2013, the Schedule 13D/A filed on May 15, 2013, the Schedule 13D/A filed on March 4, 2014, the Schedule 13D/A filed on June 11, 2015, the Schedule 13D/A filed on June 16, 2015 and the Schedule 13D/A filed on March 3, 2016, together with this Amendment No. 15, the “Schedule 13D”), and is being filed on behalf of WP X Biologics LLC, a Delaware limited liability company (“WP X B”), Warburg Pincus Private Equity X, L.P., a Delaware limited partnership (“WP X”), and holder of 96.9% of the equity interest in WP X B, Warburg Pincus X Partners, L.P., a Delaware limited partnership and holder of 3.1% of the equity interest in WP X B (“WPP X”, and together with WP X, the “Funds”), Warburg Pincus X, L.P., a Delaware limited partnership (“WP X LP”), and the general partner of each of the Funds, Warburg Pincus X GP L.P., a Delaware limited partnership (“WP X GP”), and the general partner of WP X LP, WPP GP LLC, a Delaware limited liability company (“WPP GP”), and the general partner of WP X GP, Warburg Pincus Partners, L.P., a Delaware limited partnership (“WP Partners”), and the managing member of WPP GP, Warburg Pincus Partners GP LLC, a Delaware limited liability company (“WPP GP LLC”), and the general partner of WP Partners, Warburg Pincus & Co., a New York limited liability company (“WP”), and the managing member of WPP GP LLC, Warburg Pincus LLC, a New York limited liability company (“WP LLC”), that manages each of the Funds, and Messrs. Charles R. Kaye and Joseph P. Landy, each a Managing General Partner of WP and a Co-Chief Executive Officer and Managing Member of WP LLC (each of the foregoing, a “Warburg Pincus Reporting Person” and collectively, the “Warburg Pincus Reporting Persons”). Messrs. Kaye and Landy may be deemed to control the Funds and WP X B, WP X LP, WP X GP, WPP GP, WP Partners, WPP GP LLC, WP and WP LLC. This Amendment No. 15 relates to the common stock, $0.0001 par value per share (the “Shares”), of China Biologic Products, Inc., a Delaware corporation (the “Company”).

All capitalized terms used herein which are not defined herein have the meanings given to such terms in the Original Schedule 13D, as amended.

Item 4 of the Schedule 13D is hereby supplemented by inserting the following after the last paragraph thereof:

On March 4, 2016, the Underwriter notified the Funds of its election to exercise the option to purchase additional Shares from the Funds in full.

On March 7, 2016, the Funds sold an aggregate of 4,257,000 Shares to the Underwriter at a price of $107.00 per Share pursuant to the Underwriting Agreement.

Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows:

(a) The percentages used herein are calculated based upon 26,590,974 Shares outstanding as of February 25, 2016, as reported in the Company’s Form 10-K for the year ended December 31, 2015, filed with the SEC on February 25, 2016.

WP X B is the direct owner of 3,112,920 Shares representing approximately 11.7% of the outstanding Shares of the Company. As WP X B is owned 96.9% by WP X and 3.1% by WPP X, therefore, WP X is deemed to beneficially own 3,960,496 Shares representing 14.9% of the outstanding Shares, including 944,077 Shares that it directly holds, and WPP X is deemed to beneficially own 126,704 Shares representing 0.5% of the outstanding Shares, including 30,203 Shares that it directly holds.

(b) WP X B is deemed to (i) share voting power and disposition power over 3,016,419 Shares with each of the Warburg Pincus Reporting Persons (other than WPP X) and (ii) share voting power and disposition power over 96,501 Shares with each of the Warburg Pincus Reporting Persons (other than WP X). WP X is deemed to (i) share voting power and disposition power over 3,016,419 Shares with WP X B and (ii) share voting power and disposition power over 3,960,496 Shares with each of the Warburg Pincus Reporting Persons (other than WPP X and WP X B). WPP X is deemed to (i) share voting power and disposition power over 96,501 Shares with WP X B and (ii) share voting and disposition power over 126,704 Shares with each of the Warburg Pincus Reporting Persons (other than WP X and WP X B). Each of the Warburg Pincus Reporting Persons (other than the Funds and WP X B) is deemed to (i) share voting power and disposition power over 3,112,920 Shares with WP X B and (ii) share voting power and disposition power over 4,087,200 Shares with the Funds.

(d) Except as set forth in this Item 5, no person other than each respective record owner referred to herein of the Shares is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities.

After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.


WP X BIOLOGICS LLC

By:		Warburg Pincus Private Equity X, L.P., its managing member
By:		Warburg Pincus X, L.P., its general partner
By:		Warburg Pincus X GP L.P., its general partner
By:		WPP GP LLC, its general partner
By:		Warburg Pincus Partners, L.P., its managing member
By:		Warburg Pincus Partners GP LLC, its general partner
By:		Warburg Pincus & Co., its managing member

By:		/s/ Robert B. Knauss
Name:		Robert B. Knauss
Title:		Partner

WARBURG PINCUS PRIVATE EQUITY X, L.P.

By:		Warburg Pincus X, L.P., its general partner
By:		Warburg Pincus X GP L.P., its general partner
By:		WPP GP LLC, its general partner
By:		Warburg Pincus Partners, L.P., its managing member
By:		Warburg Pincus Partners GP LLC, its general partner
By:		Warburg Pincus & Co., its managing member

By:		/s/ Robert B. Knauss
Name:		Robert B. Knauss
Title:		Partner

WARBURG PINCUS X PARTNERS, L.P.

By:		Warburg Pincus X, L.P., its general partner
By:		Warburg Pincus X GP L.P., its general partner
By:		WPP GP LLC, its general partner
By:		Warburg Pincus Partners, L.P., its managing member
By:		Warburg Pincus Partners GP LLC, its general partner
By:		Warburg Pincus & Co., its managing member

By:		/s/ Robert B. Knauss
Name:		Robert B. Knauss
Title:		Partner


Warburg Pincus X, L.P.

By:		Warburg Pincus X GP L.P., its general partner
By:		WPP GP LLC, its general partner
By:		Warburg Pincus Partners, L.P., its managing member
By:		Warburg Pincus Partners GP LLC, its general partner
By:		Warburg Pincus & Co., its managing member

By:		/s/ Robert B. Knauss
Name:		Robert B. Knauss
Title:		Partner

Warburg Pincus X GP L.P.

By:		WPP GP LLC, its general partner
By:		Warburg Pincus Partners, L.P., its managing member
By:		Warburg Pincus Partners GP LLC, its general partner
By:		Warburg Pincus & Co., its managing member

By:		/s/ Robert B. Knauss
Name:		Robert B. Knauss
Title:		Partner

WPP GP LLC

By:		Warburg Pincus Partners, L.P., its managing member
By:		Warburg Pincus Partners GP LLC, its general partner
By:		Warburg Pincus & Co., its managing member

By:		/s/ Robert B. Knauss
Name:		Robert B. Knauss
Title:		Partner

Warburg Pincus Partners, L.P.

By:		Warburg Pincus Partners GP LLC, its general partner
By:		Warburg Pincus & Co., its managing member

By:		/s/ Robert B. Knauss
Name:		Robert B. Knauss
Title:		Partner


Warburg Pincus Partners GP LLC

By:		Warburg Pincus & Co., its managing member

By:		/s/ Robert B. Knauss
Name:		Robert B. Knauss
Title:		Partner

Warburg Pincus & Co.

By:		/s/ Robert B. Knauss
Name:		Robert B. Knauss
Title:		Partner

Warburg Pincus LLC

By:		/s/ Robert B. Knauss
Name:		Robert B. Knauss
Title:		Managing Director

Charles R. Kaye

By:		/s/ Robert B. Knauss
Name:		Robert B. Knauss
Title:		Attorney-in-fact*

Joseph P. Landy

By:		/s/ Robert B. Knauss
Name:		Robert B. Knauss
Title:		Attorney-in-fact*


1.	Names of reporting persons. WP X Biologics LLC
2.	Check the appropriate box if a member of a group (see instructions). (a) ¨ (b) x
3.	SEC use only
4.	Source of funds (see instructions) N/A
5.	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ¨
6.	Citizenship or place of organization Delaware
Number of shares beneficially owned by each reporting person with		7.	Sole voting power 0
		8.	Shared voting power 3,112,920 (See Item 5)
		9.	Sole dispositive power 0
		10.	Shared dispositive power 3,112,920 (See Item 5)
11.	Aggregate amount beneficially owned by each reporting person 3,112,920 (See Item 5)
12.	Check if the aggregate amount in Row (11) excludes certain shares (see instructions) ¨
13.	Percent of class represented by amount in Row (11) 11.7% (See Item 5)
14.	Type of reporting person (see instructions) OO


1.	Names of reporting persons. Warburg Pincus Private Equity X, L.P.
2.	Check the appropriate box if a member of a group (see instructions). (a) ¨ (b) x
3.	SEC use only
4.	Source of funds (see instructions) N/A
5.	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ¨
6.	Citizenship or place of organization Delaware
Number of shares beneficially owned by each reporting person with		7.	Sole voting power 0
		8.	Shared voting power 3,960,496 (See Item 5)
		9.	Sole dispositive power 0
		10.	Shared dispositive power 3,960,496 (See Item 5)
11.	Aggregate amount beneficially owned by each reporting person 3,960,496 (See Item 5)
12.	Check if the aggregate amount in Row (11) excludes certain shares (see instructions) ¨
13.	Percent of class represented by amount in Row (11) 14.9% (See Item 5)
14.	Type of reporting person (see instructions) PN


1.	Names of reporting persons. Warburg Pincus X Partners, L.P.
2.	Check the appropriate box if a member of a group (see instructions). (a) ¨ (b) x
3.	SEC use only
4.	Source of funds (see instructions) N/A
5.	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ¨
6.	Citizenship or place of organization Delaware
Number of shares beneficially owned by each reporting person with		7.	Sole voting power 0
		8.	Shared voting power 126,704 (See Item 5)
		9.	Sole dispositive power 0
		10.	Shared dispositive power 126,704 (See Item 5)
11.	Aggregate amount beneficially owned by each reporting person 126,704 (See Item 5)
12.	Check if the aggregate amount in Row (11) excludes certain shares (see instructions) ¨
13.	Percent of class represented by amount in Row (11) 0.5% (See Item 5)
14.	Type of reporting person (see instructions) PN


1.	Names of reporting persons. Warburg Pincus X, L.P.
2.	Check the appropriate box if a member of a group (see instructions). (a) ¨ (b) x
3.	SEC use only
4.	Source of funds (see instructions) N/A
5.	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ¨
6.	Citizenship or place of organization Delaware
Number of shares beneficially owned by each reporting person with		7.	Sole voting power 0
		8.	Shared voting power 4,087,200 (See Item 5)
		9.	Sole dispositive power 0
		10.	Shared dispositive power 4,087,200 (See Item 5)
11.	Aggregate amount beneficially owned by each reporting person 4,087,200 (See Item 5)
12.	Check if the aggregate amount in Row (11) excludes certain shares (see instructions) ¨
13.	Percent of class represented by amount in Row (11) 15.4% (See Item 5)
14.	Type of reporting person (see instructions) PN


1.	Names of reporting persons. Warburg Pincus X GP L.P.
2.	Check the appropriate box if a member of a group (see instructions). (a) ¨ (b) x
3.	SEC use only
4.	Source of funds (see instructions) N/A
5.	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ¨
6.	Citizenship or place of organization Delaware
Number of shares beneficially owned by each reporting person with		7.	Sole voting power 0
		8.	Shared voting power 4,087,200 (See Item 5)
		9.	Sole dispositive power 0
		10.	Shared dispositive power 4,087,200 (See Item 5)
11.	Aggregate amount beneficially owned by each reporting person 4,087,200 (See Item 5)
12.	Check if the aggregate amount in Row (11) excludes certain shares (see instructions) ¨
13.	Percent of class represented by amount in Row (11) 15.4% (See Item 5)
14.	Type of reporting person (see instructions) PN


1.	Names of reporting persons. WPP GP LLC
2.	Check the appropriate box if a member of a group (see instructions). (a) ¨ (b) x
3.	SEC use only
4.	Source of funds (see instructions) N/A
5.	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ¨
6.	Citizenship or place of organization Delaware
Number of shares beneficially owned by each reporting person with		7.	Sole voting power 0
		8.	Shared voting power 4,087,200 (See Item 5)
		9.	Sole dispositive power 0
		10.	Shared dispositive power 4,087,200 (See Item 5)
11.	Aggregate amount beneficially owned by each reporting person 4,087,200 (See Item 5)
12.	Check if the aggregate amount in Row (11) excludes certain shares (see instructions) ¨
13.	Percent of class represented by amount in Row (11) 15.4% (See Item 5)
14.	Type of reporting person (see instructions) OO


1.	Names of reporting persons. Charles R. Kaye
2.	Check the appropriate box if a member of a group (see instructions). (a) ¨ (b) x
3.	SEC use only
4.	Source of funds (see instructions) N/A
5.	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ¨
6.	Citizenship or place of organization United States of America
Number of shares beneficially owned by each reporting person with		7.	Sole voting power 0
		8.	Shared voting power 4,087,200 (See Item 5)
		9.	Sole dispositive power 0
		10.	Shared dispositive power 4,087,200 (See Item 5)
11.	Aggregate amount beneficially owned by each reporting person 4,087,200 (See Item 5)
12.	Check if the aggregate amount in Row (11) excludes certain shares (see instructions) ¨
13.	Percent of class represented by amount in Row (11) 15.4% (See Item 5)
14.	Type of reporting person (see instructions) IN


1.	Names of reporting persons. Joseph P. Landy
2.	Check the appropriate box if a member of a group (see instructions). (a) ¨ (b) x
3.	SEC use only
4.	Source of funds (see instructions) N/A
5.	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ¨
6.	Citizenship or place of organization United States of America
Number of shares beneficially owned by each reporting person with		7.	Sole voting power 0
		8.	Shared voting power 4,087,200 (See Item 5)
		9.	Sole dispositive power 0
		10.	Shared dispositive power 4,087,200 (See Item 5)
11.	Aggregate amount beneficially owned by each reporting person 4,087,200 (See Item 5)
12.	Check if the aggregate amount in Row (11) excludes certain shares (see instructions) ¨
13.	Percent of class represented by amount in Row (11) 15.4% (See Item 5)
14.	Type of reporting person (see instructions) IN


CUSIP No. 16938C106


CUSIP No. 16938C106


CUSIP No. 16938C106


CUSIP No. 16938C106